Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Survodutide
GLP-1/glucagon dual agonist in late-stage obesity trials.
Mechanism of Action
A dual agonist of the GLP-1 and glucagon receptors. The glucagon arm adds an energy-expenditure component on top of GLP-1's appetite and glycemic effects.
Research Areas
Common Research Protocols
Phase 3 trials use weekly subcutaneous dose escalation.
Protocols summarized for educational reference from published research. Not dosing guidance.
Cited Research
Survodutide for obesity (Phase 2)
Up to ~19% mean weight loss at 46 weeks.
Important Considerations
- •Investigational; not yet FDA-approved.
- •GI side effects are dose-limiting.
Explore more peptides
Educational Information Only — Not Medical Advice
All content on this page is for educational and informational purposes only. It is not medical advice, diagnosis, or treatment. We make no claims that any peptide can diagnose, treat, cure, or prevent any disease. Peptides discussed are not FDA-approved for the indications listed unless explicitly stated otherwise.
Always consult a licensed healthcare provider before beginning any wellness protocol. Statements have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability, eligibility, and pricing may vary.
Ask the Library
Ask anything about peptides — answers come from our curated reference library with citations.